We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TESARO Shares Rally on Rumors of Potential Acquisition Offer
Read MoreHide Full Article
Shares of TESARO, Inc. rallied more than 15% on Tuesday on rumors that it may have received a buyout offer. According to a Bloomberg report published on Nov 16, the company is working with financial advisers for a potential sale by designing a deal and pursuing prospective suitors. The acquisition rumors were strengthened further by TESARO’s announcement yesterday that it will not attend an upcoming conference, as stated in a Motley Fool article. Generally, companies cancel participation at important events if there are some potential strategic activities underway like a possible sale.
The Bloomberg report also states that the consistent decline in the share price of TESARO has made it significantly cheaper. Consequently, any company with focus on oncology will be able to make a buyout offer. Gilead Sciences (GILD) is being looked at as a potential buyer. TESARO’s market valuation stands at $2.3 billion as of Nov 20.
TESARO’s shares have slumped 49.4% so far this year compared with the industry’s decline of 6.2%.
Shares of the company have been declining owing to rising competition in the PARP inhibitor segment. TESARO’s marketed product portfolio consist of a single product, Zejula. It is a PARP inhibitor which is approved as maintenance treatment for ovarian cancer irrespective of BRCA mutation. Although the drug has seen strong uptake since its launch, the rising competition and the stagnating market share of PARP inhibitors in the ovarian cancer market is a concern. AstraZeneca (AZN - Free Report) and Merck’s (MRK - Free Report) Lynparza and Clovis Oncology’s Rubraca compete with Zejula in the PARP inhibitor segment.
With these four companies duking it out for market share in the segment, all of them are trying to develop their respective drugs in additional indications. This increases the operating expenses for these companies, consequently hurting margins. However, we note that Lynparza is being developed by two of the large-cap pharmaceuticals companies which have a huge capital to continue clinical studies in several indications. Meanwhile, Clovis and TESARO have a single product in their marketed portfolio and depend on it for revenues. This is likely to impact their cash position significantly if the drugs cannot perform well. High cash burn and low revenues will continue to hurt these companies over the long haul.
We remind investors that AstraZeneca’s label expansion application for Lynparza in first-line maintenance treatment for advanced ovarian cancer, the largest ovarian cancer market, received priority review earlier this month. Although the other two companies are also developing their drugs in the first-line setting, they will fall behind Lynparza as their studies are expected to complete in 2019 or beyond. This is likely to make gaining market share in the first-line setting more competitive for these two drugs.
Moreover, Clovis and TESARO have to pay royalties on the sales of their drugs to Pfizer and Merck, respectively, under a license agreement. Any modification to these agreements can also hamper the prospect of these companies.
Consequently, a buyout offer from any large pharmaceutical company for TESARO will be a significant relief for its investors as they can sell their stake in the company at a higher price. Any buyout offer gives a premium to the current stock price as we have seen in several blockbuster deals concluded in 2018.
Any confirmed offer for TESARO is likely to boost buyout potential of Clovis which may fuel a rally in the latter’s stock price as well. Investors should remain focused on news on these two companies to see how things pan out.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
TESARO Shares Rally on Rumors of Potential Acquisition Offer
Shares of TESARO, Inc. rallied more than 15% on Tuesday on rumors that it may have received a buyout offer. According to a Bloomberg report published on Nov 16, the company is working with financial advisers for a potential sale by designing a deal and pursuing prospective suitors. The acquisition rumors were strengthened further by TESARO’s announcement yesterday that it will not attend an upcoming conference, as stated in a Motley Fool article. Generally, companies cancel participation at important events if there are some potential strategic activities underway like a possible sale.
The Bloomberg report also states that the consistent decline in the share price of TESARO has made it significantly cheaper. Consequently, any company with focus on oncology will be able to make a buyout offer. Gilead Sciences (GILD) is being looked at as a potential buyer. TESARO’s market valuation stands at $2.3 billion as of Nov 20.
TESARO’s shares have slumped 49.4% so far this year compared with the industry’s decline of 6.2%.
Shares of the company have been declining owing to rising competition in the PARP inhibitor segment. TESARO’s marketed product portfolio consist of a single product, Zejula. It is a PARP inhibitor which is approved as maintenance treatment for ovarian cancer irrespective of BRCA mutation. Although the drug has seen strong uptake since its launch, the rising competition and the stagnating market share of PARP inhibitors in the ovarian cancer market is a concern. AstraZeneca (AZN - Free Report) and Merck’s (MRK - Free Report) Lynparza and Clovis Oncology’s Rubraca compete with Zejula in the PARP inhibitor segment.
With these four companies duking it out for market share in the segment, all of them are trying to develop their respective drugs in additional indications. This increases the operating expenses for these companies, consequently hurting margins. However, we note that Lynparza is being developed by two of the large-cap pharmaceuticals companies which have a huge capital to continue clinical studies in several indications. Meanwhile, Clovis and TESARO have a single product in their marketed portfolio and depend on it for revenues. This is likely to impact their cash position significantly if the drugs cannot perform well. High cash burn and low revenues will continue to hurt these companies over the long haul.
We remind investors that AstraZeneca’s label expansion application for Lynparza in first-line maintenance treatment for advanced ovarian cancer, the largest ovarian cancer market, received priority review earlier this month. Although the other two companies are also developing their drugs in the first-line setting, they will fall behind Lynparza as their studies are expected to complete in 2019 or beyond. This is likely to make gaining market share in the first-line setting more competitive for these two drugs.
Moreover, Clovis and TESARO have to pay royalties on the sales of their drugs to Pfizer and Merck, respectively, under a license agreement. Any modification to these agreements can also hamper the prospect of these companies.
Consequently, a buyout offer from any large pharmaceutical company for TESARO will be a significant relief for its investors as they can sell their stake in the company at a higher price. Any buyout offer gives a premium to the current stock price as we have seen in several blockbuster deals concluded in 2018.
Any confirmed offer for TESARO is likely to boost buyout potential of Clovis which may fuel a rally in the latter’s stock price as well. Investors should remain focused on news on these two companies to see how things pan out.
TESARO, Inc. Price
TESARO, Inc. Price | TESARO, Inc. Quote
Zacks Rank
TESARO currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>